Ciaftalan

Ciaftalan

SCHEMBL483723

Cl.[AlH3].c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc(nc4[nH]c(n1)c1ccccc41)-c1ccccc1-3)c1ccccc21

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Ciaftalan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 known ✓ P09874 1/20 0.32
GLA known ✓ P06280 1/20 0.32
GAA known ✓ P10253 1/20 0.32
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
TDP1 Q9NUW8 4/20 0.44
RECQL P46063 3/20 0.44
THRB P10828 1/20 0.44
APEX1 P27695 1/20 0.44
BLM P54132 1/20 0.44
CA5A P35218 1/20 0.39
CYP1A2 P05177 4/20 0.34
CYP2D6 P10635 4/20 0.34
CYP2C19 P33261 4/20 0.34
CYP3A4 P08684 3/20 0.34
HSD17B10 Q99714 3/20 0.34
USP2 O75604 1/20 0.34
ALOX15 P16050 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
ALDH1A1 P00352 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ciaftalan SCHEMBL9317824 1.00 MEN1 (0.44) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL18587431 0.98 MEN1 (0.45) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL14691323 0.98 MEN1 (0.45) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL31085 0.98 MEN1 (0.45) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL1160674 0.98 MEN1 (0.45) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL31084 0.98 MEN1 (0.45) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL14691039 0.98 MEN1 (0.45) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL1024190 0.98 MEN1 (0.45) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL23270396 0.96 MEN1 (0.44) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL1023666 0.96 MEN1 (0.44) MEN1KMT2ATDP1RECQLTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727503-A2 INCREASING ADHESION BETWEEN VITREOUS AND RETINA The Regents of the University of California (US) 2026-04-22 EP claimed
US-20260058190-A1 High Voltage Battery Cell, Module or Pack Having a Rolled Structure and Production Method HONEYCOMB BATTERY COMPANY (US) 2026-02-26 US claimed
US-12476244-B2 Surface-stabilized cathode active material particles, lithium secondary batteries containing same, and method of manufacturing HONEYCOMB BATTERY COMPANY (US) 2025-11-18 US claimed
CN-119371384-A Catalyst, system and method for preparing succinic anhydride by oxo-oxidation of ethylene oxide 上海交通大学 2025-01-28 CN claimed
US-12211998-B2 Method and system for aromatic macrocyclic compounds (phthalocyanines) as cathode additives for inhibition of transition metal dissolution and stable solid electrolyte interphase formation ENEVATE CORPORATION (US) 2025-01-28 US claimed
WO-2024259148-A2 INCREASING ADHESION BETWEEN VITREOUS AND RETINA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-19 WO claimed
CN-110915049-B Polymer layer for protecting lithium anode of lithium metal secondary battery and manufacturing method thereof 纳米技术仪器公司 2024-10-25 CN claimed
US-12057548-B2 Continuous process for producing electrochemical cells HONEYCOMB BATTERY COMPANY (US) 2024-08-06 US claimed
CN-110710023-B Lithium metal secondary battery comprising anode-protecting polymer layer and method for manufacturing same 纳米技术仪器公司 2023-11-03 CN claimed
CN-110612633-B Non-combustible quasi-solid electrolyte and lithium secondary battery containing same 纳米技术仪器公司 2023-09-12 CN claimed
EP-0786820-A2 Organic thin film transistor with enhanced carrier mobility MOTOROLA, INC. (US) 1997-07-30 EP claimed
US-5120649-A Contacting with photoreactive compound, light and oxygen NEW YORK BLOOD CENTER, INC. (US) 1992-06-09 US claimed
US-5035968-A Electrography, sensitivity, durability FUJI PHOTO FILM CO., LTD. (JP) 1991-07-30 US claimed
US-4973536-A LAMINATED STRUCTURE OF CHARGE GENERATING AND CHARGE TRANSPORTING LAYERS FUJI PHOTO FILM CO., LTD. (JP) 1990-11-27 US claimed
EP-0183570-B1 OPTICAL RECORDING MEDIUM AND OPTICAL DISC NEC CORPORATION (JP) 1989-08-02 EP claimed
US-4814245-A HIGH PHOTOSENSITIVITY; EXCELLENT DURABILITY; COPIERS; PRINTERS USING LASERS OR CATHODE RAY TUBES FUJI PHOTO FILM CO., LTD. (JP) 1989-03-21 US claimed
US-4740447-A SUBSTRATE, TWO SPACER LAYERS HAVING DIFFERENT REFRACTIVE INDICES, RECORDING LAYER NEC CORPORATION (JP) 1988-04-26 US claimed
EP-0183570-A2 Optical recording medium and optical disc NEC CORPORATION (JP) 1986-06-04 EP claimed
US-4535043-A ALUMINUM CHLORIDE PHTHALOCYANINE AND A HYDRAZONE COMPOUND FOR CHARGE GENERATION AND TRANSPORT CANON KABUSHIKI KAISHA (JP) 1985-08-13 US claimed
US-4251607-A HAVING A PHTHALOCYANINE OR PORPHIN FUNCTION AND AN ANODE OF A GROUP 1A METAL NIPPON TELEGRAPH AND TELEPHONE PUBLIC CORPORATION (JP) 1981-02-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260058190-A1 High Voltage Battery Cell, Module or Pack Having a Rolled Structure and Production Method ITGB1, CACNA2D1, ITGA1 PARP1 349/4885GLA 1296/4885GAA 3236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.